

ESHB 1879 - S COMM AMD

By Committee on Health & Long Term Care

ADOPTED 04/12/2019

1 Strike everything after the enacting clause and insert the
2 following:

3 "NEW SECTION. **Sec. 1.** A new section is added to chapter 48.43
4 RCW to read as follows:

5 The definitions in this section apply throughout this section and
6 sections 2 and 3 of this act unless the context clearly requires
7 otherwise.

8 (1) "Clinical practice guidelines" means a systemically developed
9 statement to assist decision making by health care providers and
10 patients about appropriate health care for specific clinical
11 circumstances and conditions.

12 (2) "Clinical review criteria" means the written screening
13 procedures, decision rules, medical protocols, and clinical practice
14 guidelines used by a health carrier or prescription drug utilization
15 management entity as an element in the evaluation of medical
16 necessity and appropriateness of requested prescription drugs under a
17 health plan.

18 (3) "Emergency fill" means a limited dispensed amount of
19 medication that allows time for the processing of prescription drug
20 utilization management.

21 (4) "Medically appropriate" means prescription drugs that under
22 the applicable standard of care are appropriate: (a) To improve or
23 preserve health, life, or function; (b) to slow the deterioration of
24 health, life, or function; or (c) for the early screening,
25 prevention, evaluation, diagnosis, or treatment of a disease,
26 condition, illness, or injury.

27 (5) "Prescription drug utilization management" means a set of
28 formal techniques used by a health carrier or prescription drug
29 utilization management entity, that are designed to monitor the use
30 of or evaluate the medical necessity, appropriateness, efficacy, or
31 efficiency of prescription drugs including, but not limited to, prior
32 authorization and step therapy protocols.

1 (6) "Prescription drug utilization management entity" means an
2 entity affiliated with, under contract with, or acting on behalf of a
3 health carrier to perform prescription drug utilization management.

4 (7) "Prior authorization" means a mandatory process that a
5 carrier or prescription drug utilization management entity requires a
6 provider or facility to follow to determine if a service is a benefit
7 and meets the requirements for medical necessity, clinical
8 appropriateness, level of care, or effectiveness in relation to the
9 applicable plan.

10 (8) "Step therapy protocol" means a protocol or program that
11 establishes the specific sequence in which prescription drugs for a
12 specified medical condition will be covered by a health carrier.

13 NEW SECTION. **Sec. 2.** A new section is added to chapter 48.43
14 RCW to read as follows:

15 For health plans delivered, issued for delivery, or renewed on or
16 after January 1, 2021, clinical review criteria used to establish a
17 prescription drug utilization management protocol must be evidence-
18 based and updated on a regular basis through review of new evidence,
19 research, and newly developed treatments.

20 NEW SECTION. **Sec. 3.** A new section is added to chapter 48.43
21 RCW to read as follows:

22 For health plans delivered, issued for delivery, or renewed on or
23 after January 1, 2021:

24 (1) When coverage of a prescription drug for the treatment of any
25 medical condition is subject to prescription drug utilization
26 management, the patient and prescribing practitioner must have access
27 to a clear, readily accessible, and convenient process to request an
28 exception through which the prescription drug utilization management
29 can be overridden in favor of coverage of a prescription drug
30 prescribed by a treating health care provider. A health carrier or
31 prescription drug utilization management entity may use its existing
32 medical exceptions process to satisfy this requirement. The process
33 must be easily accessible on the health carrier and prescription drug
34 utilization management entity's web site. Approval criteria must be
35 clearly posted on the health carrier and prescription drug
36 utilization management entity's web site. This information must be in
37 plain language and understandable to providers and patients.

1 (2) Health carriers must disclose all rules and criteria related
2 to the prescription drug utilization management process to all
3 participating providers, including the specific information and
4 documentation that must be submitted by a health care provider or
5 patient to be considered a complete exception request.

6 (3) An exception request must be granted if the health carrier or
7 prescription drug utilization management entity determines that the
8 evidence submitted by the provider or patient is sufficient to
9 establish that:

10 (a) The required prescription drug is contraindicated or will
11 likely cause a clinically predictable adverse reaction by the
12 patient;

13 (b) The required prescription drug is expected to be ineffective
14 based on the known clinical characteristics of the patient and the
15 known characteristics of the prescription drug regimen;

16 (c) The patient has tried the required prescription drug or
17 another prescription drug in the same pharmacologic class or a drug
18 with the same mechanism of action while under his or her current or a
19 previous health plan, and such prescription drug was discontinued due
20 to lack of efficacy or effectiveness, diminished effect, or an
21 adverse event;

22 (d) The patient is currently experiencing a positive therapeutic
23 outcome on a prescription drug recommended by the patient's provider
24 for the medical condition under consideration while on his or her
25 current or immediately preceding health plan, and changing to the
26 required prescription drug may cause clinically predictable adverse
27 reactions, or physical or mental harm to, the patient; or

28 (e) The required prescription drug is not in the best interest of
29 the patient, based on documentation of medical appropriateness,
30 because the patient's use of the prescription drug is expected to:

31 (i) Create a barrier to the patient's adherence to or compliance
32 with the patient's plan of care;

33 (ii) Negatively impact a comorbid condition of the patient;

34 (iii) Cause a clinically predictable negative drug
35 interaction; or

36 (iv) Decrease the patient's ability to achieve or maintain
37 reasonable functional ability in performing daily activities.

38 (4) Upon the granting of an exception, the health carrier or
39 prescription drug utilization management entity shall authorize

1 coverage for the prescription drug prescribed by the patient's
2 treating health care provider.

3 (5) (a) For nonurgent exception requests, the health carrier or
4 prescription drug utilization management entity must:

5 (i) Within three business days notify the treating health care
6 provider that additional information, as disclosed under subsection
7 (2) of this section, is required in order to approve or deny the
8 exception request, if the information provided is not sufficient to
9 approve or deny the request; and

10 (ii) Within three business days of receipt of sufficient
11 information from the treating health care provider as disclosed under
12 subsection (2) of this section, approve a request if the information
13 provided meets at least one of the conditions referenced in
14 subsection (3) of this section or if deemed medically appropriate, or
15 deny a request if the requested service does not meet at least one of
16 the conditions referenced in subsection (3) of this section.

17 (b) For urgent exception requests, the health carrier or
18 prescription drug utilization management entity must:

19 (i) Within one business day notify the treating health care
20 provider that additional information, as disclosed under subsection
21 (2) of this section, is required in order to approve or deny the
22 exception request, if the information provided is not sufficient to
23 approve or deny the request; and

24 (ii) Within one business day of receipt of sufficient information
25 from the treating health care provider as disclosed under subsection
26 (2) of this section, approve a request if the information provided
27 meets at least one of the conditions referenced in subsection (3) of
28 this section or if deemed medically appropriate, or deny a request if
29 the requested service does not meet at least one of the conditions
30 referenced in subsection (3) of this section.

31 (c) If a response by a health carrier or prescription drug
32 utilization management entity is not received within the time frames
33 established under this section, the exception request is deemed
34 granted.

35 (d) For purposes of this subsection, exception requests are
36 considered urgent when an enrollee is experiencing a health condition
37 that may seriously jeopardize the enrollee's life, health, or ability
38 to regain maximum function, or when an enrollee is undergoing a
39 current course of treatment using a nonformulary drug.

1 (6) Health carriers must cover an emergency supply fill if a
2 treating health care provider determines an emergency fill is
3 necessary to keep the patient stable while the exception request is
4 being processed. This exception shall not be used to solely justify
5 any further exemption.

6 (7) When responding to a prescription drug utilization management
7 exception request, a health carrier or prescription drug utilization
8 management entity shall clearly state in their response if the
9 exception request was approved or denied. The health carrier must use
10 clinical review criteria as referenced in section 2 of this act for
11 the basis of any denial. Any denial must be based upon and include
12 the specific clinical review criteria relied upon for the denial and
13 include information regarding how to appeal denial of the exception
14 request. If the exception request from a treating health care
15 provider is denied for administrative reasons, or for not including
16 all the necessary information, the health carrier or prescription
17 drug utilization management entity must inform the provider what
18 additional information is needed and the deadline for its submission.

19 (8) The health carrier or prescription drug utilization
20 management entity must permit a stabilized patient to remain on a
21 drug during an exception request process.

22 (9) A health carrier must provide sixty days' notice to providers
23 and patients for any new policies or procedures applicable to
24 prescription drug utilization management protocols. New health
25 carrier policies or procedures may not be applied retroactively.

26 (10) This section does not prevent:

27 (a) A health carrier or prescription drug utilization management
28 entity from requiring a patient to try an AB-rated generic equivalent
29 or a biological product that is an interchangeable biological product
30 prior to providing coverage for the equivalent branded prescription
31 drug;

32 (b) A health carrier or prescription drug utilization management
33 entity from denying an exception for a drug that has been removed
34 from the market due to safety concerns from the federal food and drug
35 administration; or

36 (c) A health care provider from prescribing a prescription drug
37 that is determined to be medically appropriate.

38 NEW SECTION. **Sec. 4.** The insurance commissioner shall adopt
39 rules necessary for the implementation of this act."

ESHB 1879 - S COMM AMD

By Committee on Health & Long Term Care

ADOPTED 04/12/2019

1 On page 1, line 2 of the title, after "benefits;" strike the
2 remainder of the title and insert "adding new sections to chapter
3 48.43 RCW; and creating a new section."

EFFECT: (1) Adds a definition for "prescription drug utilization
management entity" and replaces references to "review organization."
(2) Makes technical changes to clarify language.

--- END ---